Form 4: Femasys Inc. CFO Acquires Stock Options
SEC Form 4 Filing
Femasys Inc.'s Chief Financial Officer, Dov Elefant, acquired stock options for 186,345 shares of common stock on January 28, 2025.
Summary
- Dov Elefant, the Chief Financial Officer of Femasys Inc., has acquired stock options for 186,345 shares of the company's common stock.
- The options are divided into two grants: one for 72,045 shares and another for 114,300 shares.
- Both grants have an exercise price of $1.05 per share.
- The options vest over a four-year period, starting on January 28, 2025, contingent on continued employment with Femasys or a subsidiary.
- The options expire on January 28, 2035.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.
Positives
- The acquisition of stock options by the CFO aligns his interests with the long-term success of the company.
- The vesting schedule encourages continued employment and commitment from the CFO.
Risks
- The value of the stock options is dependent on the future performance of Femasys Inc.'s stock price.
- If the CFO leaves the company before the options fully vest, he may forfeit some or all of the options.
Future Outlook
The stock options will vest over the next four years, contingent on the CFO's continued employment.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology and medical device industry, aligning management's interests with shareholder value creation.
Comparison to Industry Standards
- Stock option grants are a standard practice for executive compensation in the biotech industry.
- Vesting schedules of 4 years are common to encourage long term commitment.
- The exercise price of $1.05 is not comparable without knowing the current market price of the stock.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the CFO to work towards increasing the company's value.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 01/28/2025 | Date of stock option grant and start of vesting period. |
| 01/28/2035 | Expiration date of the stock options. |
| 01/30/2025 | Date of filing of the SEC Form 4. |
Keywords
stock options, Femasys Inc, CFO, Dov Elefant, equity, vesting, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.